Literature DB >> 15014731

Stereoisomers in Psychiatry: The Case of Escitalopram.

William J. Burke1, Christopher J. Kratochvil.   

Abstract

Many medications in common clinical use consist of "mirror image" isomers that differ only in the direction in which they rotate plane-polarized light. These stereoisomers exist as mixtures of "right" and "left" handed molecules that are the product of chemical syntheses. However, the biochemical milieu of the human body is a highly stereospecific environment where the fit of medication and receptor may depend on the shape of the molecule in 3-dimensional space. Recent advances in chemistry have allowed the more ready preparation of single isomers of various drugs that were previously available only as racemic mixtures. For those compounds in which the isomers differ in stereospecificity, this separation into single isomers can result in significant changes in potency, tolerability, and efficacy. This article reviews some basic information about stereochemistry and describes the development of a new single isomer antidepressant, escitalopram, which is one of the components of the widely used selective serotonin uptake inhibitor citalopram.

Entities:  

Year:  2002        PMID: 15014731      PMCID: PMC314378          DOI: 10.4088/pcc.v04n0107

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  15 in total

Review 1.  Chiral switches.

Authors:  G T Tucker
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

2.  Parasitology. Close encounters: good, bad, and ugly.

Authors:  E Pennisi
Journal:  Science       Date:  2000-11-24       Impact factor: 47.728

Review 3.  Three-dimensional view of pharmacology.

Authors:  I W Wainer
Journal:  Am J Hosp Pharm       Date:  1992-09

4.  Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.

Authors:  William J Burke; Ivan Gergel; Anjana Bose
Journal:  J Clin Psychiatry       Date:  2002-04       Impact factor: 4.384

Review 5.  Stereochemical aspects of pharmacotherapy.

Authors:  D R Brocks; F Jamali
Journal:  Pharmacotherapy       Date:  1995 Sep-Oct       Impact factor: 4.705

6.  The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer.

Authors:  J Hyttel; K P Bøgesø; J Perregaard; C Sánchez
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 7.  Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.

Authors:  C Sánchez; J Hyttel
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

8.  Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

Authors:  Jack M Gorman; Andrew Korotzer; Guojin Su
Journal:  CNS Spectr       Date:  2002-04       Impact factor: 3.790

Review 9.  Chirality and drugs used in psychiatry: nice to know or need to know?

Authors:  R M Lane; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 10.  Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.

Authors:  P Baumann; B Rochat
Journal:  Int Clin Psychopharmacol       Date:  1995-03       Impact factor: 1.659

View more
  7 in total

Review 1.  Single-enantiomer drugs: elegant science, disappointing effects.

Authors:  Peter Mansfield; David Henry; Anne Tonkin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

Review 3.  (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Authors:  Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-12-16       Impact factor: 4.530

Review 4.  MDMA to Treat PTSD in Adults.

Authors:  Dustin Latimer; Michael D Stocker; Kia Sayers; Jackson Green; Adam M Kaye; Alaa Abd-Elsayed; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-06-01

Review 5.  Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).

Authors:  Antonio Del Casale; Serena Sorice; Alessio Padovano; Maurizio Simmaco; Stefano Ferracuti; Dorian A Lamis; Chiara Rapinesi; Gabriele Sani; Paolo Girardi; Georgios D Kotzalidis; Maurizio Pompili
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

6.  1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.

Authors:  Origène Nyanguile; Frederik Pauwels; Walter Van den Broeck; Carlo W Boutton; Ludo Quirynen; Tania Ivens; Liesbet van der Helm; Geneviève Vandercruyssen; Wendy Mostmans; Frédéric Delouvroy; Pascale Dehertogh; Maxwell D Cummings; Jean-Francois Bonfanti; Kenneth A Simmen; Pierre Raboisson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

7.  An emerging role for escitalopram in the treatment of obsessive-compulsive disorder.

Authors:  Dawson W Hedges; Fu Lye M Woon
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.